- Home
- DRUG vs RIGL Comparison
DRUG vs RIGL Comparison
Compare DRUG & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DRUG | RIGL |
|---|---|---|
| Founded | 2019 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 778.4M | 884.9M |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | DRUG | RIGL |
|---|---|---|
| Price | $54.20 | $49.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $152.35 | $63.00 |
| AVG Volume (30 Days) | 106.2K | ★ 194.5K |
| Earning Date | 08-17-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 1.32 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | $3.89 |
| Revenue Next Year | N/A | $21.95 |
| P/E Ratio | ★ N/A | $36.91 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $47.23 | $24.84 |
| 52 Week High | $123.75 | $52.24 |
Technical Indicators
Market Signals| Indicator | DRUG | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 42.51 | 59.28 |
| Support Level | N/A | $33.93 |
| Resistance Level | $78.35 | $49.50 |
| Average True Range (ATR) | 3.35 | 1.86 |
| MACD | 0.66 | -0.07 |
| Stochastic Oscillator | 47.50 | 74.01 |
Price Performance
Historical ComparisonAbout DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.